Global pharmaceutical companies are increasingly pivoting their business models in China, moving away from traditional, asset-heavy operations toward strategic investments in local biotechnology firms. According to industry experts speaking at the Global Health Summit in Hong Kong, this shift is designed to capitalize on the rapid innovation and significant valuation growth potential found within the Chinese biotech sector.

Xu Chenming, head of the healthcare group at Citic Securities, noted that multinational corporations are re-evaluating their presence in the region. Rather than maintaining large-scale physical infrastructure, these firms are choosing to act as investors and partners for emerging Chinese biotech companies. This strategy allows global giants to gain access to new medical technologies and research pipelines while mitigating the risks associated with managing large, capital-intensive facilities in a changing regulatory and economic environment. The trend reflects a broader effort by global pharma to integrate more deeply with local Chinese research ecosystems to remain competitive in the global market.